Advertisement
HIMS vs SKIN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HIMS is a Hold and SKIN is a Hold.
HIMS in upward trend: 10-day moving average broke above 50-day moving average on October 22, 2026
The 10-day moving average for HIMS crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on HIMS as a result. In 67 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
Following a +4.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where HIMS advanced for three days, in 238 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 61 cases where HIMS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for HIMS turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 38 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
HIMS moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
HIMS broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for HIMS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.972) is normal, around the industry mean (10.407). P/E Ratio (-46.984) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (2.624) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (2.686) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. HIMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 73 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Momentum Indicator for SKIN turns negative, indicating new downward trend
SKIN saw its Momentum Indicator move below the 0 level on October 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned negative. In 91 of the 95 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for SKIN turned negative on September 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SKIN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for SKIN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SKIN's RSI Oscillator exited the oversold zone, 27 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 66 cases where SKIN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
Following a +16.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where SKIN advanced for three days, in 194 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
SKIN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (25.985) is normal, around the industry mean (21.044). SKIN has a moderately low P/E Ratio (-48.239) as compared to the industry average of (16.942). Projected Growth (PEG Ratio) (0.858) is also within normal values, averaging (1.518). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (0.302) is also within normal values, averaging (1.931).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. SKIN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SKIN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
HIMS | SKIN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 77 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 67 Overvalued | 45 Fair valued | |
PROFIT vs RISK RATING 1..100 | 73 | 100 | |
SMR RATING 1..100 | 97 | 98 | |
PRICE GROWTH RATING 1..100 | 71 | 84 | |
P/E GROWTH RATING 1..100 | 98 | 16 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SKIN's Valuation (45) in the null industry is in the same range as HIMS (67). This means that SKIN’s stock grew similarly to HIMS’s over the last 12 months.
HIMS's Profit vs Risk Rating (73) in the null industry is in the same range as SKIN (100). This means that HIMS’s stock grew similarly to SKIN’s over the last 12 months.
HIMS's SMR Rating (97) in the null industry is in the same range as SKIN (98). This means that HIMS’s stock grew similarly to SKIN’s over the last 12 months.
HIMS's Price Growth Rating (71) in the null industry is in the same range as SKIN (84). This means that HIMS’s stock grew similarly to SKIN’s over the last 12 months.
SKIN's P/E Growth Rating (16) in the null industry is significantly better than the same rating for HIMS (98). This means that SKIN’s stock grew significantly faster than HIMS’s over the last 12 months.
| HIMS | SKIN | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 79% |
| Stochastic ODDS (%) | 1 day ago 80% | 1 day ago 82% |
| Momentum ODDS (%) | 1 day ago 81% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 83% | 2 days ago 90% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 89% |
| TrendMonth ODDS (%) | 1 day ago 81% | 1 day ago 89% |
| Advances ODDS (%) | 3 days ago 86% | 8 days ago 79% |
| Declines ODDS (%) | 9 days ago 82% | 4 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 77% | 1 day ago 84% |
| Aroon ODDS (%) | 1 day ago 80% | 1 day ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HIMS’s FA Score shows that 0 FA rating(s) are green while SKIN’s FA Score has 1 green FA rating(s).
- HIMS’s FA Score: 0 green, 5 red.
- SKIN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HIMS’s TA Score shows that 3 TA indicator(s) are bullish while SKIN’s TA Score has 4 bullish TA indicator(s).
- HIMS’s TA Score: 3 bullish, 6 bearish.
- SKIN’s TA Score: 4 bullish, 4 bearish.
Price Growth
HIMS (@Pharmaceuticals: Generic) experienced а -0.85% price change this week, while SKIN (@Household/Personal Care) price change was -11.94% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.00%. For the same industry, the average monthly price growth was -9.86%, and the average quarterly price growth was +9.31%.
The average weekly price growth across all stocks in the @Household/Personal Care industry was +2.34%. For the same industry, the average monthly price growth was +2.17%, and the average quarterly price growth was +13.17%.
Reported Earning Dates
HIMS is expected to report earnings on Nov 09, 2026.
SKIN is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-3.00% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Household/Personal Care (+2.34% weekly)Household/Personal Care companies sell products for home cleaning and/or personal hygiene and grooming purposes. Products of this industry include detergents, shampoos, soaps, cosmetics, fabric conditioners and infant care fragrances. Procter & Gamble, Unilever, Estee Lauder and Colgate-Palmolive are some of the biggest names in the business. A lot of the products become a necessary part of people’s daily routine, and therefore the industry is relatively less vulnerable to macroeconomic downturns. At the same time, product quality, consumer safety, and ease of use are extremely critical factors for a company to survive competition and earn recognition in this industry.
Advertisement
HIMS and
Correlation & Price change
A.I.dvisor tells us that HIMS and COTY have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HIMS and COTY's prices will move in lockstep.
| Ticker / NAME | Correlation To HIMS | 1D Price Change % | ||
|---|---|---|---|---|
| HIMS | 100% | -0.27% | ||
| COTY - HIMS | 31% Poorly correlated | +5.25% | ||
| HROW - HIMS | 25% Poorly correlated | -0.32% | ||
| IRWD - HIMS | 25% Poorly correlated | +0.56% | ||
| EVO - HIMS | 24% Poorly correlated | -1.28% | ||
| IPAR - HIMS | 24% Poorly correlated | +2.54% | ||
More | ||||
SKIN and
Correlation & Price change
A.I.dvisor tells us that SKIN and COTY have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SKIN and COTY's prices will move in lockstep.
| Ticker / NAME | Correlation To SKIN | 1D Price Change % | ||
|---|---|---|---|---|
| SKIN | 100% | +0.59% | ||
| COTY - SKIN | 29% Poorly correlated | +5.25% | ||
| HNST - SKIN | 25% Poorly correlated | N/A | ||
| HIMS - SKIN | 23% Poorly correlated | -0.27% | ||
| NUS - SKIN | 22% Poorly correlated | +3.36% | ||
| ACU - SKIN | 22% Poorly correlated | +1.53% | ||
More | ||||